Baseline | End of follow-up | |||||
---|---|---|---|---|---|---|
NAFLD group | AFLD group | p-value | NAFLD group | AFLD group | p-value | |
n = 151 | n = 94 | n = 151 | n = 94 | |||
Gender (F/M) | 105/46 | 31/63 | <0.001 | |||
Female% | 70% | 33% | ||||
Mean (sd) or Median (IQR) | Mean (sd) or Median (IQR) | |||||
Age (years) | 54 (14.7) | 51 (13.5) | NS | |||
BMI (kg/m2) | 29 (26–32) | 29 (25–32) | NS | |||
AST (U/L) | 47 (32–63) | 76 (44–157) | <0.001 | 48 (36; 28–46) | 91 (46; 28–93) | 0.05 |
ALT (U/L) | 69 (44–102) | 109 (58–198) | 0.001 | 44 (36; 26–52) | 67 (45; 27–75) | 0.04 |
Bilirubin (μmol/L) | 10 (7-15) | 12 (9-21) | 0.01 | 14 (9; 7–18) | 49 (11; 9–21) | NS |
ALP (U/L) | 197 (135–320) | 179 (134–280) | NS | 196 (122; 87–157) | 172 (119; 77–179) | NS |
Prothrombin time (sec) | 13 (12-14) | 14 (13-15) | 0.02 | 16 (14; 13–17) | 16 (14; 13–17) | NS |
Albumin (g/L) | 40 (36–44) | 39 (32–41) | NS | 37 (39; 33–42) | 35 (37; 28–41) | NS |
Platelets (x109/L) | 265 (92.9) | 228 (83.3) | 0.006 | 235 (238; 170–281) | 219 (222; 152–265) | NS |
Random blood glucose (mmol/L) | 6 (5-7) | 6 (5-7) | NS | 7 (6; 5–7) | 7 (6; 5–7) | NS |
Cholesterol (mmol/L) | 6 (5,6) | 5 (5-7) | NS | 5 (5; 4–6) | 5(5; 4–6) | NS |
Triglycerides (mmol/L) | 2 (1-3) | 2 (1-3) | NS | 2 (2; 1–2) | 2 (2; 1–2) | NS |
MCV (fL) | 90 (6.1) | 95 (7.2) | <0.001 | 90 (90; 87–94) | 95 (95; 90–105) | <0.001 |